Aldeyra The (ALDX NASDAQ) stock market data APIs
$4.8561
0.12(2.5%)
as of September 17, 2025
Try our APIs with
free plan!
Aldeyra The Financial Data Overview
Price chart is built with
Anychart
Aldeyra Therapeutics, Inc., a biotechnology company, discovers and develops therapies designed to treat immune-mediated and metabolic diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP) modulator, which is in Phase III clinical trial for the treatment of dry eye disease and allergic conjunctivitis; and ADX-2191, a dihydrofolate reductase inhibitor for the treatment retinitis pigmentosa. The company also develops ADX-629, an orally administered RASP modulator that is in Phase 2 clinical trials for the treatment of COVID-19, atopic asthma, psoriasis, and alcohol intoxication. In addition, it develops preclinical RASP platform, including ADX 248, ADX 743, ADX 631, ADX 246, and other product candidates in development for inflammatory and metabolic diseases. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was incorporated in 2004 and is based in Lexington, Massachusetts.
Prev. Close
4.8561
Open
4.9774
High
5.0691
Low
4.8359
52 wk Range
1.14-7.2
Market Cap
294 M
Shares Outstanding
60 046 K
EPS
-0.16
Beta
0.789
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Aldeyra The (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Aldeyra The data using free add-ons & libraries
Get Aldeyra The Fundamental Data
Aldeyra The Fundamental data includes:
- Net Revenue:
- EBITDA: -53 061 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-08-08
- EPS/Forecast: -0.2433
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Aldeyra The News
New
Alkermes appoints new CFO
* Joshua Reed has been appointed as chief financial officer of Alkermes (NASDAQ:ALKS [https://seekingalpha.com/symbol/ALKS]), effective September 15, 2025. * Reed previously served as CFO of Omeg...
Alkermes Appoints Joshua Reed as Chief Financial Officer
DUBLIN, Sept. 12, 2025 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) is pleased to announce the appointment of Joshua Reed as Chief Financial Officer (CFO), effective Monday, Sept. 15, 2025. Mr. Reed wi...
High Growth Tech Stocks To Watch In US August 2025
In August 2025, the United States stock market has been experiencing a mixed performance, with major indices like the Dow Jones Industrial Average and S&P 500 retreating slightly from record highs due...
JonesTrading Lifts Aldeyra Therapeutics, Inc. (ALDX) Price Target to $9
Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) is among the best US stocks under $10 to invest in. Catherine Novack, an analyst at JonesTrading, has raised the price target on Aldeyra Therapeutics, Inc. (NA...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
